FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
May 08, 2023 16:00 ET
|
FibroGen, Inc.
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential...